BPI 2026 · Biotech

Prime Medicine at BPI 2026

Cambridge, Massachusetts

Prime Medicine brings 2 presentations to BPI 2026 in Boston. Its sessions focus on analytics for prime editing therapies. One describes platform liquid chromatography assays that characterize multi-component RNA-LNP products, and another uses automation and AI to speed potency assay validation.

OrganizationBPI 2026 Attendance
Prime Medicine
Cambridge, Massachusetts
1 Director of Automation & Assays · 1 Analytical Development Scientist II
Biotech
Biotechnology company developing gene editing therapies based on prime editing, delivered with technologies such as RNA-lipid nanoparticles.
Talk
Wed Sep 23
1:00pm–1:45pm
From Bench to BLA: Automation and AI-Accelerated Potency Assay Validation
Scientific Lunch Presentation 7
Digital Biomanufacturing & AICell & Gene Therapy
Talk
Thu Sep 24
2:45pm–3:15pm
Leveraging Platform-Based, Multi-Attribute LC Assays to Characterize Multi-components Prime Editing (PE) RNA-LNP
Development of Emerging Cell & Gene Therapies

Explore the full BPI 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full BPI 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Prime Medicine

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by Informa Connect or the BioProcess International Conference & Exhibition. Submit a correction